- Algernon NeuroScience has completed dosing of the second cohort in its Phase 1 clinical study of an intravenous formulation of DMT
- The study aims to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of six hours
- Algernon Pharmaceuticals plans to design Phase 2 studies for the continued investigation of DMT for stroke and traumatic brain injury (TBI)
- Algernon Pharmaceuticals (AGN) opened trading at $0.26
Algernon’s (AGN) subsidiary, Algernon NeuroScience, has completed the dosing the second cohort in its Phase 1 clinical study of N,N-Dimethyltryptamine (DMT).
The escalating dose Phase 1 clinical study is assessing an intravenous formulation of DMT.
The safety review committee has also approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues. The trial is being conducted at the Centre for Human Drug Research (CHDR) in Leiden, Netherlands.
The study aims to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of six hours, a period that has never been studied clinically.
The second part of the study will include dosing subjects for six hours with repeated dosing over a two-week period.
Algernon Pharmaceuticals plans to design Phase 2 studies for the continued investigation of DMT for stroke and traumatic brain injury (TBI).
DMT is a hallucinogenic tryptamine drug that produces effects similar to those of other psychedelics, such as LSD, ketamine, psilocybin, and psilocin and occurs naturally in many plant species and animals, including humans.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease. Its private subsidiary, Algernon NeuroScience, is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury.
Algernon Pharmaceuticals (AGN) opened trading at $0.26.
